Background/Aims: The treatment for chronic hepatitis C (CHC) is removal of the virus in order to prevent progression to liver cirrhosis and hepatocellular carcinoma (HCC). Few data have been presented regarding the clinical significance of changes in the alanine aminotransferase (ALT) level in this context. We analyzed the patterns of changes in ALT level and investigated the relationship between the rapid normalization of ALT and sustained virologic response (SVR) after combined treatment with peginterferon and ribavirin. Methods: CHC patients (n=370) were classified into four groups according to the initial ALT level and subsequent changes: (1) initially abnormal ALT level and sustained abnormal ALT level during treatment, (2) initially abnormal ALT level but achievement of ALT normalization, (3) initially normal ALT level and variable ALT abnormality during treatment, and (4) initially normal ALT level and sustained normalization of ALT level during treatment. We subdivided groups 1 and 2 into those with patterns of decreased and normalization of ALT, with or without rapid normalization. We checked the end-treatment response (ETR) and SVR rates in each group and the factors associated with SVR, including patterns of changes in ALT level. OR=2.76, P=0.017), and initial hepatitis C virus RNA titer (OR=0.28, 95% CI=0.10-0.75, P=0.012) were identified as independent significant predictive factors for SVR.
INTRODUCTION
Hepatitis C virus (HCV) infection is an important cause of chronic liver disease and primary hepatocellular carcinoma (HCC) in the world. 1 The likelihood of achieving sustained virological response (SVR) could be predicted based on several factors, including virus genotype, age, sex, histological finding and initial HCV RNA titer. These factors have been reported in many previous studies, 2,3 but 
PATIENTS AND METHODS

Patients
We retrospectively reviewed the medical records of 
Study design
ALT patterns were analyzed throughout the course of treatment and follow-up period. We categorized patients into four groups according to initial ALT levels and ALT variability during treatment: group 1, patients who had initial abnormal ALT levels and sustained abnormal ALT levels during treatment (Gr 1), group 2, patients who had initial abnormal ALT levels and obtained normalization of ALT (Gr 2), group 3, patients who had initial normal ALT levels and variable ALT abnormality during treatment (Gr 3) and group 4, patients who had initial normal ALT levels and sustained normal ALT levels during treatment (Gr 4) (Fig. 1) .
We compared the end treatment response (ETR) and SVR rates between groups, based on the eradication of virus (Table 1) .
Also for analysis of decreased and normalization of ALT pattern, patients who had initial abnormal ALT levels (i.e.
Gr 1 and 2) were subdivided into two groups: (1) patients who had initial abnormal ALT levels with rapid normalization, i.e. within 1.5 times of normal range of ALT 4 weeks after starting treatment and (2), patients who had initial abnormal ALT levels without rapid normalization, i.e. not within 1.5
times of normal range of ALT 4 weeks after starting treatment. and 800 mg per day of oral ribavirin for 24 weeks. 
Treatment with peg-interferon plus ribavirin
Clinical and laboratory assessment
We followed patients by performing blood samples and measuring biochemical variables. Blood samples were tested for complete blood counts (CBC), serum ALT levels, AST was considered to be 40 IU/L, which is the upper normal limit in our laboratory.
Assessment of efficacy
The primary end point of efficacy was SVR. i.e. the undetectable serum HCV RNA levels at 24 weeks after 
Statistical analysis
Data management and statistical analyses were performed with SPSS software version 15.0 (SPSS Inc., Chicago, IL).
Rates and proportions were calculated for categorical data. Univariate analysis and multiple logistic regression were used to identify predictive factors for sustained response.
In multiple logistic regression analysis, we determined the strength of influence of possible variables (age, viral genotype, HCV RNA titer and ALT variability) for sustained response.
A P-value of <0.05 was considered as statistically significant. 
RESULTS
Patient demographics
Of the 370 patients, 202 patients withdrew because of adverse events, were lost during follow-up, or were on treatment or diagnosed with co-infection with hepatitis B or other liver disease. Total 168 patients followed up for at least 6 months after treatment ended were finally enrolled. The baseline characteristics of the patients are summarized in 
Virologic responses according to ALT variability during treatment
For analysis purposes, patients were divided into four groups based on initial ALT levels and ALT variability during treatment. Of the 168 patients treated with peg-interferonribavirin combination, 115 (68.45%) showed SVR and 53 (31.55%) showed non-sustained response. The ETR and SVR rates in the four groups were listed in Table 1 . The ETR rates was not significantly different between the four groups.
The SVR rate was significantly lower in group 1 compared with group 2 patients (37.8 vs. 81.6%, P-value <0.001), but was not different between group 3 and 4.
Virologic responses according to rapid/non-rapid normalization of ALT levels 4 weeks after treatment For analysis purposes, the baseline characteristics of the patients who had initial abnormal ALT levels are summarized in 
Analysis of factors that predicted sustained virological response to combination therapy
We performed univariate analysis using the chi-square (Table 3) .
Among patients who had initial abnormal ALT levels (Gr 1-2), the SVR rate was significantly higher in group 2, compared with group 1. In the multiple logistic regression, compared to group 1, group 2 had significantly higher SVR Figure 2 . Comparison of virologic responses in patients with or without rapid normalization of an initially abnormal ALT level according to genotype. Group 1, initially abnormal ALT level with rapid normalization (i.e., within 1.5 times the normal range of ALT level by 4 weeks after starting treatment). Group 2, initially abnormal ALT level without rapid normalization (i.e., not within 1.5 times the normal range of ALT level by 4 weeks after starting treatment). Levels of statistical significance (i.e., P) were calculated using the chi-squared test. SVR, sustained virologic response. 
DISCUSSION
Chronic hepatitis C (CHC) is the third most common cause of chronic liver disease and HCC in Korea, following hepatitis B virus (HBV) infection and alcohol. 5 The successful treatment of CHC is measured by the virological and biochemical response and by histological improvement to clearance of virus, for preventing liver cirrhosis and HCC.
There were attempts to determine non-responders as early as possible in order to avoid prolonged treatment without benefits. 6 In an effort to determine whether patients could be preselected for treatment, many studies have attempted to identify clinical or virological features that may distinguish CHC patients who may or may not respond to interferon therapy. 3, 7 Those studies showed that pretreatment prognostic features statistically associated with favorable response included younger age, female gender and absence of cirrhosis. Low levels of pretreatment serum HCV RNA and the presence of viral genotype other than 1 were also reported to be associated with favorable response to CHC therapy. 2, 3, 8 However, there were patients who had responded to combination therapy, but did not meet the specified pretreatment characteristics. 7 Thus, the effort to identify useful predictive markers, especially during treatment is still necessary.
In the natural history of HCV infection, it is well known that the first detectable biochemical marker is the presence of HCV RNA and elevation of ALT level may occur, within 4 to 12 weeks. 9 Although this elevation reflected hepatocyte damage, ALT level may fluctuate sometimes, and a single value in the normal range can neither rule out active infection nor help gauge the severity of underlying liver disease. 10 In general, decreased pattern of ALT level is the accepted basic indicator of interferon therapeutic effect in CHC, and several studies have shown that delayed showed persistently elevated ALT levels during treatment;
in contrast, in the study by Zeuzem et al 13 using peg-interferon and ribavirin, 41% of patients did not achieve ALT normalization until the end of therapy. These findings seem to suggest that lack of ALT normalization is not necessarily associated with decreased efficacy of treatment. However, this phenomenon has not been systematically characterized, and little is known about its incidence and clinical characteristics in chronic hepatitis C patients treated with peg-interferon and ribavirin combination therapy.
In our study, we subdivided patients into four groups, Results of this study are subjected to some limitations.
First, the study had retrospective and observational design and was conducted in a single institution. Thus, our results may not reflect a general situation. Second, our analysis was carried out in a relatively small number of patients, and it will be interesting to determine whether this incidence and association holds true in larger groups of patients. Third, we did not investigate chronic hepatitis C patients according to disease progression, including cirrhosis and hepatocellular carcinoma, and did not include patients with liver disease of other origins. Thus, in future studies, analysis of ALT variability during treatment should be performed according to liver status. Fourth, several factors previously known as main putative causes for ALT variability, were not investigated in our study (i.e. thyroid dysfunction, lipid profile, HOMA-IR, the use of herb medication and alcohol consumption).
In conclusion, in patients with initial abnormal ALT levels, the SVR rate was significantly associated with ALT normalization during combination therapy; ALT normalization during treatment might be considered as useful predictive factor for obtaining SVR in patients with initial abnormal ALT levels. In particular, rapid normalization of ALT 4
weeks after treatment in genotype 1 group might be considered an indicator of favorable response to treatment, readily available in clinical practice.
